Genmab — Marts 2018
-
God morgen.
-
Genmab får skovlen under rival i patenttvist
Genmabs tyske rival må se sig slået i fejden om et af de patenter, der relaterer sig til milliardmidlet Darzalex.
(medwatch.dk)
-
Dejligt , så undgår vi lidt uro der.. måske det endda kan blive lidt positivt
-
Det havde jeg ikke set
-
Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma (REBUILD) NCT03475628 - https://clinicaltrials.gov/ct2/show/NCT03475628?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=03%2F22%2F2018&rank=2
-
the presentation Rachel gave is available for replay. I think she did this rather well. I also liked the little promo video in the middle.
https://www.prnewswire.com/news-releases/genmab-as-to-present-at-the-dbvic---deutsche-bank-adr-virtual-investor-conference-on-march-22-2018-300617571.html -
God morgen.
-
Tak for henvisning tl Medwatch. En gammel nyhed som jeg også havde overset. Se samme her: http://borsen.dk/nyheder/virksomheder/artikel/1/354045/genmab_faar_delsejr_i_amerikansk_patenttvist.html
-
Det burde være en civil case og burde dermed kunne findes her: https://courtconnect.courts.delaware.gov/public/ck_public_qry_main.cp_main_idx Men jeg vælter mig ikke ligefrem i søgeresultater...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind